首页> 外文期刊>European Journal of Cancer Supplements >2062 POSTER Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective

【24h】

2062 POSTER Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective

机译：2062 POSTER比较绝经后激素受体阳性（HR +）妇女中的前期来曲唑或阿那曲唑或切换的依西美坦与他莫昔芬治疗早期乳腺癌的成本-效果比较

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2007年第4期|共2页
作者
F.Di Trapani; J.Karnon; S.Kaura;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. Comparison of the cost-effectiveness of upfront letrozole or anastrozole versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women -the Cypriot perspective [J] . D.Andreopoulos, J.Karnon, S.Kaura European Journal of Cancer Supplements . 2008,第7期

机译：前期来曲唑或阿那曲唑与他莫昔芬对绝经后激素受体阳性（HR +）妇女早期乳腺癌的成本效益比较-塞浦路斯观点
2. 2092 POSTER Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective [J] . K.El Ouagari, J.Karnon, S.Kaura European Journal of Cancer Supplements . 2007,第4期

机译：2092 POSTER比较芳香化酶抑制剂来曲唑，阿那曲唑或依西美坦与他莫昔芬与他莫昔芬治疗激素受体阳性绝经后早期乳腺癌的成本效益比较：加拿大的观点
3. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. [J] . Delea TE, El-Ouagari K, Karnon J, Breast cancer research and treatment. . 2008,第3期

机译：从加拿大的角度来看，来曲唑与他莫昔芬作为激素治疗阳性的绝经后绝经后妇女的初始辅助治疗的成本效益。
4. Study on the Efficacy Evaluation of Oral Sequential Tamoxifen in Postmenopausal Women with Hormone-dependent Breast Cancer [C] . Na Li, Yahua Sun, Sheng Zhao, International Conference on Life Sciences, Medicine, and Health . 2018

机译：激素依赖性乳腺癌后代妇女口腔序列儿毒素疗效评价研究
5. A randomized double-blind controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer [O] . Hiroji Iwata, Norikazu Masuda, Shinji Ohno, -1

机译：依西美坦与阿那曲唑的随机双盲对照研究用于绝经后日本女性激素受体阳性晚期乳腺癌的一线治疗
6. PCN97 A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB + ANASTROZOLE COMPARED TO LAPATINIB + LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS) [O] . McNamara S, Moore L, Ray J 2010

机译：PCN97成本效益分析：使用曲妥珠单抗+纳曲唑与拉帕替尼+左唑，左雷唑单药治疗或阿那曲唑单药疗法治疗HER2 + /激素受体阳性（HR +）转移性肝癌转移服务（NHS）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号